sincalide has been researched along with Liver-Cirrhosis* in 3 studies
1 review(s) available for sincalide and Liver-Cirrhosis
Article | Year |
---|---|
[Cholecystokinin-pancreozymin (CCK-PZ)].
Topics: Acute Disease; Biomarkers; Chronic Disease; Diagnostic Techniques, Endocrine; Humans; Jaundice, Obstructive; Liver Cirrhosis; Pancreatitis; Radioimmunoassay; Sincalide; Specimen Handling | 2005 |
2 other study(ies) available for sincalide and Liver-Cirrhosis
Article | Year |
---|---|
Plasma cholecystokinin-octapeptide like immunoreactivity in patients with hepatic cirrhosis.
Molecular forms of cholecystokinin (CCK) in the peripheral circulation were studied in normal subjects and cirrhotic patients. Fractionation of plasma extract collected 20 min after intraduodenal infusion of fat revealed four major peaks by Sephadex G-50 column chromatography in normal subjects. Peak I eluted at a position similar to CCK-33, peaks II and III eluted between CCK-33 and CCK-14, and peak IV eluted between CCK-14 and CCK-8. In cirrhotic patients, there was a prominent peak (peak V) eluted at a position similar to CCK-8, in addition to those four peaks. These findings are consistent with the previous observations of hepatic elimination of CCK-8, and suggest that smaller forms of CCK similar in size to CCK-8 are not major forms of CCK in plasma in normal subjects but circulate substantially in cirrhotic patients. Topics: Cholecystokinin; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Peptide Fragments; Sincalide | 1987 |
Marked prolongation in disappearance half-time of plasma cholecystokinin-octapeptide in patients with hepatic cirrhosis.
For exploration on the elimination of cholecystokinin from the circulation, the disappearance half-time of cholecystokinin-octapeptide was estimated with cholecystokinin specific radioimmunoassay in normal subjects and patients with chronic renal failure and with hepatic cirrhosis. With a brief infusion of 30.4 ng/kg of cholecystokinin-octapeptide for 2 min, plasma cholecystokinin level rose from 16.1 +/- 3.6 pg/ml (mean +/- SE) to 216.5 +/- 6.1 pg/ml at 3 min after starting infusion, and decreased rapidly in a single exponential fashion for 10 min in hepatic cirrhosis. The disappearance half-time of cholecystokinin-octapeptide in patients with hepatic cirrhosis was 2.45 +/- 0.07 min, and it was significantly longer than that in normal subjects (1.30 +/- 0.07) or patients with chronic renal failure (1.70 +/- 0.11). These findings suggest that the liver plays a major role in cholecystokinin-octapeptide elimination in humans. Topics: Adult; Female; Half-Life; Humans; Kidney Failure, Chronic; Liver; Liver Cirrhosis; Male; Middle Aged; Radioimmunoassay; Sincalide | 1985 |